The European Parliament recently adopted first-reading of the Critical Medicines Act, expanding "collaborative procurement and solidarity mechanisms, explicitly acknowledging their relevance to specialized treatments, including in oncology." Now entering interinstitutional negotiations, the Critical Medicines Act ensures that continuity of care for cancer patients will remain a key focus area for European Union health policy.
To read more about the Critical Medicines Act, click here.
Researchers from the Gray Faculty of Medical and Health Sciences in Tel Aviv, in partnership with researchers in 14 laboratories in Israel, USA, Italy, Germany, Poland, and Austria, have uncovered "a mechanism that allows breast cancer to send metastases to the brain - a highly lethal occurrence for which there is currently no effective treatment." Following injection of cancer cells with or without functional gene P53, results indicated that "cells with disrupted P53 activity thrived much more." These findings are crucial towards developing new drugs and personalized monitoring for early detection and treatment of brain metastases.
Click here to learn more.
Source:
Laue K, Pozzi S, Zerbib J, et al. p53 inactivation drives breast cancer metastasis to the brain through SCD1 upregulation and increased fatty acid metabolism. Nat Genet. Published online December 29, 2025. doi:10.1038/s41588-025-02446-1
